TRADE REMEDIES | 2026-05-16

Section 232 Pharmaceutical Onshoring Agreements: Commerce Department Establishes June 12 Application Deadline for Patented Drug Manufacturers Seeking Reduced 20 Percent Tariff Treatment Through 2030 — California Life Sciences Importer Strategic Considerations and Compliance Roadmap

On May 11, 2026, the U.S. Department of Commerce, through the Bureau of Industry and Security, established procedures for pharmaceutical manufacturers to apply for Onshoring Agreements that would reduce Section 232 tariffs from 100 percent to 20 percent on imported patented pharmaceutical products and pharmaceutical ingredients, with applications due to pharma232@bis.doc.gov by June 12, 2026, and the most favorable zero percent tariff treatment available to companies that simultaneously enter into most-favored-nation pricing agreements.

By Anatolii Trembach, Esq. (California State Bar No. 349304; LL.M., USC Gould School of Law; admitted to the U.S. Court of International Trade), Trembach Law Firm, APC · Published

On May 16, 2026, California pharmaceutical importers, life sciences manufacturers, and biotechnology companies are confronting one of the most consequential trade compliance deadlines of 2026 following the U.S. Department of Commerce's May 11, 2026 announcement of operational procedures for the Section 232 Pharmaceutical Onshoring Agreement program.

Contact Trembach Law Firm at (818) 514-7680 for a confidential consultation.

Trembach Law Firm | 27001 Agoura Road, Suite 350, Calabasas, CA 91301